What is the recommended management for a patient with heart failure with mildly reduced ejection fraction (HFmrEF) (ejection fraction 40‑49%)?

Management of Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)

Start an SGLT2 inhibitor (empagliflozin 10mg daily or dapagliflozin 10mg daily) immediately as first-line therapy, then add evidence-based beta-blockers, ACEi/ARB/ARNi, and mineralocorticoid receptor antagonists, particularly for patients with LVEF on the lower end of the 41-49% spectrum. 1

Initial Diagnostic Confirmation

• Obtain two consecutive LVEF measurements using echocardiography or cardiac MRI to confirm LVEF is 41-49% and avoid misclassification from measurement variability 2
• Measure natriuretic peptides (BNP or NT-proBNP) to support the diagnosis and provide prognostic information, though normal levels do not exclude HFmrEF 2
• Assess baseline renal function, electrolytes (especially potassium), blood pressure, and heart rate before initiating therapy 3

Four-Pillar Pharmacologic Approach

First Priority: SGLT2 Inhibitors (Class 2a Recommendation)

• Initiate empagliflozin 10mg daily or dapagliflozin 10mg daily at full dose immediately as the strongest evidence-based therapy for HFmrEF 1
• SGLT2 inhibitors reduce HF hospitalizations and cardiovascular mortality with a 21% reduction in the composite endpoint driven by a 29% reduction in HF hospitalization in the EMPEROR-Preserved trial 1
• This benefit is consistent across the LVEF spectrum of 41-49%, though there may be slightly less benefit at LVEF >62.5% 1
• No dose titration is required, and these agents have minimal blood pressure effects 3

Second Priority: Evidence-Based Beta-Blockers (Class 2b Recommendation)

• Start carvedilol 3.125mg twice daily, metoprolol succinate 12.5-25mg daily, or bisoprolol 1.25mg daily if heart rate >50 bpm 3
• Titrate every 1-2 weeks toward target doses: carvedilol 25-50mg twice daily, metoprolol succinate 200mg daily, or bisoprolol 10mg daily 3, 2
• Beta-blockers reduce all-cause and cardiovascular mortality in HFmrEF based on meta-analysis of 575 patients with LVEF 40-49% 1
• The benefit is particularly strong for patients with LVEF on the lower end of the 41-49% spectrum who respond similarly to HFrEF patients 1

Third Priority: ACEi/ARB/ARNi (Class 2b Recommendation)

• Prefer sacubitril/valsartan (ARNi) 24/26mg or 49/51mg twice daily over ACEi or ARB based on superior outcomes in the PARAGON-HF subgroup analysis 1
• In PARAGON-HF, sacubitril-valsartan reduced the composite endpoint (rate ratio 0.78; 95% CI 0.64-0.95) in patients with LVEF 45-57% 1
• If ARNi is not feasible, start enalapril 2.5-5mg twice daily or lisinopril 2.5-5mg daily and titrate to target doses 2
• Titrate ARNi toward 97/103mg twice daily over several weeks if systolic blood pressure remains >100 mmHg 3

Fourth Priority: Mineralocorticoid Receptor Antagonists (Class 2b Recommendation)

• Add spironolactone 12.5-25mg daily or eplerenone 25mg daily for symptomatic patients, especially those with LVEF closer to 40% 1
• In TOPCAT post-hoc analysis of 520 patients with LVEF 44-49%, spironolactone reduced cardiovascular death and HF hospitalization 1
• Contraindicated if eGFR <30 mL/min/1.73m² or potassium >5.0 mmol/L 3
• Monitor potassium and creatinine 1-2 weeks after initiation, then monthly for 3 months, then every 3 months 3

Practical Titration Strategy

• Initiate SGLT2 inhibitor and one other medication class simultaneously (weeks 1-2), typically the beta-blocker if heart rate >70 bpm 3
• Add one additional medication class every 1-2 weeks based on hemodynamic tolerance 3, 2
• Prioritize beta-blocker up-titration if heart rate >70 bpm, ARNi/ACEi up-titration if systolic BP >100 mmHg, and MRA up-titration if potassium <4.5 mmol/L with stable renal function 3
• Aim for at least 50% of target doses for each medication class to achieve clinically meaningful benefit 2

Management of Common Barriers

• Asymptomatic low blood pressure (90-100 mmHg): Continue all medications at current doses; low BP alone does not predict adverse outcomes and does not require dose reduction 3
• Symptomatic hypotension (SBP <80 mmHg): Temporarily reduce the most recently up-titrated drug, but never discontinue SGLT2 inhibitor or MRA for low BP alone 3
• Bradycardia (HR <50 bpm): Reduce beta-blocker dose by 50%; if HR remains ≥70 bpm in sinus rhythm, consider adding ivabradine 2.5-5mg twice daily 3
• Hyperkalemia (K+ >5.5 mmol/L): Temporarily hold MRA, optimize diuretics, and consider potassium binders; restart MRA at lower dose once K+ <5.0 mmol/L 3

Diuretic Management

• Use loop diuretics (furosemide, bumetanide, torsemide) as needed for volume overload, but recognize they do not reduce mortality 2
• Adjust diuretic doses when initiating SGLT2 inhibitors to prevent excessive diuresis 3

Serial Monitoring and Trajectory Assessment

• Repeat echocardiography every 6-12 months to track LVEF trajectory, as approximately 27% of HFmrEF patients decline to LVEF ≤40% while 45% improve to LVEF ≥50% 2
• If LVEF declines to ≤40% (HFrEF), intensify all four medication classes to full target doses and reassess for device therapy eligibility after 3 months of optimal medical therapy 1, 3
• If LVEF improves to >40% (HFimpEF), continue all HFrEF/HFmrEF medications indefinitely because withdrawal is associated with relapse of ventricular dysfunction 1
• Schedule clinical follow-up every 3-6 months to assess symptoms, medication tolerance, blood pressure, renal function, and electrolytes 2

Device Therapy Considerations

• ICD is not routinely indicated in HFmrEF with LVEF 41-49%, as primary prevention trials enrolled patients with LVEF ≤35% 2
• Reassess for ICD eligibility if LVEF declines to ≤35% after ≥3 months of optimal medical therapy with expected survival >1 year 2
• CRT is not indicated unless LVEF falls to ≤35% with left bundle branch block (QRS ≥150 ms) and sinus rhythm 2

Special Populations

• African-American patients with NYHA class III-IV symptoms: Add hydralazine 37.5mg three times daily plus isosorbide dinitrate 20mg three times daily, titrating to hydralazine 75mg TID and isosorbide dinitrate 40mg TID 3
• Patients with atrial fibrillation: Aggressively up-titrate beta-blocker for rate control; add digoxin 0.125mg daily if insufficient (avoid amiodarone for rate control) 3

Evidence Strength and Nuances

The 2022 ACC/AHA/HFSA guidelines explicitly state that HFmrEF represents a dynamic spectrum, and patients with LVEF on the lower end (41-44%) respond to medical therapies similarly to HFrEF patients 1. The strongest evidence comes from EMPEROR-Preserved for SGLT2 inhibitors (Class 2a), while recommendations for beta-blockers, ARNi/ACEi/ARB, and MRAs are weaker (Class 2b) because they derive from post-hoc subgroup analyses rather than prospective trials 1. A 2024 network meta-analysis demonstrated that the combination of ARNi, MRA, and SGLT2 inhibitor provides the greatest benefit (HR 0.56 for CV death/HF hospitalization), with the most pronounced effect in HFmrEF compared to higher LVEF ranges 4. Real-world evidence from the Swedish HF Registry confirms that 84% of HFmrEF patients receive RASI/ARNI and 88% receive beta-blockers, with both associated with lower mortality and morbidity 5.

Critical Pitfall to Avoid

Do not withhold guideline-directed medical therapy awaiting symptom development or further LVEF decline—early treatment in HFmrEF reduces mortality and prevents progression to overt HF 2. The evidence base, while derived from post-hoc analyses, consistently demonstrates benefit across multiple medication classes, particularly for patients with LVEF closer to 40% 1, 6.